Related Experiment Video
Updated: Jun 20, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pharmacogenetics in cardiovascular antithrombotic therapy
Francisco Marín1, Rocío González-Conejero, Piera Capranzano
1Department of Cardiology, Hospital Universitario Virgen de Arrixaca, Murcia, Spain.
Journal of the American College of Cardiology
|September 12, 2009
Summary
Individual genetic differences, known as pharmacogenetics, significantly impact how patients respond to antithrombotic drugs, affecting treatment efficacy and safety for thrombosis and stroke. Understanding these genetic variations is key to personalized antithrombotic therapy.
Area of Science:
- Pharmacology
- Genetics
- Cardiovascular Medicine
Background:
- Thrombosis is a primary cause of coronary artery disease and embolic stroke.
- Antithrombotic therapy is crucial but shows variable patient responses.
- Interindividual heterogeneity in treatment response necessitates further investigation.
Purpose of the Study:
- To review the role of genetic polymorphisms in individual responses to antithrombotic drugs.
- To explore how pharmacogenetics influences antithrombotic drug efficacy and safety.
- To highlight the importance of personalized medicine in antithrombotic treatment.
Main Methods:
- Review of existing literature on pharmacogenetics and antithrombotic therapy.
- Analysis of studies identifying gene variants affecting drug response.
- Synthesis of information on polymorphisms impacting drug disposition, metabolism, transporters, and targets.
Main Results:
- Specific gene polymorphisms significantly modulate patient responses to antithrombotic agents.
- Variations in drug metabolism and target genes explain a portion of treatment heterogeneity.
- Pharmacogenetic factors influence both the efficacy and safety profiles of antithrombotic drugs.
Conclusions:
- Pharmacogenetics plays a critical role in interindividual variability of antithrombotic drug response.
- Identifying relevant polymorphisms can optimize antithrombotic therapy selection and dosing.
- Personalized pharmacogenetic approaches promise improved outcomes in managing thrombotic conditions.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...